Skip to main content
Premium Trial:

Request an Annual Quote


NEW YORK, Feb 15 – Due to strong sales of its MassArray SNP analysis technology, Sequenom reported increased revenues for the fourth quarter and year-end Thursday, while expenses also doubled from the fourth quarter of 1999.

Sequenom’s fourth quarter revenues totaled $3.7 million, compared to $98,000 for the year-ago quarter, and year-end revenues totaled $10 million, compared to $179,000 for 1999.

In 2000, Sequenom placed 22 MassArray systems in seven different countries. The company has signed partnerships to identify medically relevant SNPs in certain population groups with Incyte, GlaxoSmithKline, Gemini Genomics, the National Cancer Institute and the University of Texas Southwestern Medical Center.

“2000 was the year of debuts for Sequenom," CEO Toni Schuh said in a statement. "We initiated sales of our first product, the MassARRAY system, listed publicly on the Nasdaq stock market and proved that full genome screens are possible.”

The company’s expenses for the quarter also increased, to $13.8 million, in comparison to $6.8 million for the same period in 1999.For the fiscal year 2000, total costs and expenses were $47.2 million compared to $22.9 million for 1999.

Sequenom attributed these increased expenses to investment in its programs to validate genes and genetic markers, as well as increased in its sales, marketing and R&D staff.

Sequenom’s R&D expenses increased to $6.8 million for the quarter compared to $3.1 million in the same period of1999, and $19.1 million for the year compared to $10.2 million for 1999. Sales, general and administrative expenses nearly doubled for the quarter, to $4.6 million from $2.9 million for the fourth quarter of 1999, and for the year to $18.5 million, from $8.2 million for 1999.

At the year-end, Sequenom had $138.4 million in cash assets, and $166.2 million in total assets.

The Scan

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Whale Decline Analysis

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.